Regenerative Mucosal Therapies for Refractory ENT Disorders

Abstract

Refractory ear, nose, and throat (ENT) disorders present significant therapeutic challenges due to persistent mucosal dysfunction and inadequate response to conventional treatments. Recent advances in regenerative medicine have fostered the development of innovative mucosal therapies, including cell-based, growth factor, and biomaterial approaches, offering renewed potential for tissue repair and functional restoration. This review synthesizes the current evidence for regenerative mucosal therapies in refractory ENT conditions, outlining mechanisms, clinical applications, and future directions to guide clinicians in evidence-based practice.

Introduction

Refractory ENT disorders encompass a spectrum of chronic diseases such as chronic rhinosinusitis, atrophic rhinitis, and chronic otitis media that are unresponsive to standard medical and surgical interventions. Traditional approaches often fail to address the underlying mucosal pathology, leading to persistent symptoms and disease recurrence. Regenerative mucosal therapies, leveraging principles of tissue engineering and regenerative medicine, aim to restore mucosal integrity and function. This review provides a comprehensive update on the epidemiology, pathophysiology, clinical features, diagnostic strategies, and emerging regenerative treatments for refractory ENT disorders.

Epidemiology / Disease Burden

Chronic ENT disorders afflict millions worldwide, with chronic rhinosinusitis alone affecting approximately 11% of the global population. Refractory cases defined by persistent symptoms despite optimal therapy account for a significant subset, associated with impaired quality of life, increased healthcare utilization, and substantial socioeconomic burden. Atrophic rhinitis and recalcitrant otitis media, though less prevalent, contribute disproportionately to morbidity, particularly in aging populations and those with immunocompromised states. The burden of these conditions underscores the need for innovative therapies targeting mucosal regeneration.

Pathophysiology

Refractory ENT disorders often arise from chronic inflammation, repeated injury, and impaired mucosal healing. Disruption of the epithelial barrier, loss of ciliated and secretory cell function, and extracellular matrix degradation are hallmarks of mucosal dysfunction. In chronic rhinosinusitis, persistent inflammation and remodeling lead to polyp formation and compromised mucociliary clearance. Atrophic rhinitis involves progressive mucosal thinning, glandular atrophy, and bone exposure, while chronic otitis media features defective epithelial repair and persistent perforations. Failure to restore normal mucosal structure perpetuates the disease process.

Risk Factors

Key risk factors for refractory ENT disorders include recurrent infections, allergic inflammation, environmental exposures (e.g., pollutants, tobacco smoke), underlying systemic diseases (such as diabetes and autoimmune conditions), and prior surgical interventions. Genetic predisposition and impaired host defense mechanisms further contribute to disease persistence. Understanding these risk factors aids in identifying candidates most likely to benefit from regenerative therapies and informs preventive strategies.

Clinical Features

Patients with refractory ENT disorders typically present with chronic symptoms resistant to standard management. In chronic rhinosinusitis, these include persistent nasal obstruction, mucopurulent discharge, facial pain, and hyposmia. Atrophic rhinitis is characterized by nasal crusting, fetor, epistaxis, and paradoxical nasal obstruction despite wide nasal cavities. Chronic otitis media may manifest as persistent otorrhea, conductive hearing loss, and tympanic membrane perforations. These features reflect ongoing mucosal dysfunction and incomplete healing.

Diagnosis

Diagnosis of refractory ENT disorders requires a combination of clinical evaluation, endoscopic assessment, and radiologic imaging. Nasal endoscopy and otoscopy allow direct visualization of mucosal changes, polyps, crusting, or perforations. Computed tomography (CT) or magnetic resonance imaging (MRI) delineates disease extent and guides management. Histopathologic analysis may reveal features of chronic inflammation, epithelial atrophy, or fibrosis. Microbiological studies aid in excluding persistent infection. Accurate diagnosis is essential for tailoring regenerative therapeutic approaches.

Treatment & Management

Conventional management strategies include prolonged antibiotic or antifungal therapy, corticosteroids, saline irrigation, and surgical interventions such as functional endoscopic sinus surgery (FESS) or tympanoplasty. However, these measures frequently provide incomplete or transient benefit in refractory cases. The limitations of standard therapies necessitate the exploration of regenerative mucosal approaches aimed at promoting tissue repair, modulating inflammation, and restoring mucosal function.

Recent Advances / Emerging Therapies

Regenerative mucosal therapies have emerged as promising modalities for refractory ENT disorders. Mesenchymal stem cell (MSC) therapy, administered topically or via scaffold-based delivery, has demonstrated efficacy in promoting epithelial regeneration, reducing fibrosis, and modulating local immune responses in preclinical and early clinical studies. Platelet-rich plasma (PRP) delivers autologous growth factors that enhance angiogenesis and epithelial proliferation, with encouraging results in chronic rhinosinusitis and tympanic membrane repair. Bioengineered scaffolds, incorporating biocompatible materials and extracellular matrix components, provide structural support and cues for endogenous cell migration and differentiation. Gene therapy and exosome-based approaches represent cutting-edge strategies under investigation, targeting molecular pathways critical for mucosal repair. Collectively, these advances hold potential for durable symptom relief and functional restoration.

Guideline Recommendations

While regenerative mucosal therapies are not yet standard of care, several expert consensus statements and emerging guidelines endorse their use in select refractory cases within clinical trials or specialized centers. The European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS 2020) acknowledges the potential of regenerative approaches, particularly for recalcitrant disease. Ongoing multicenter randomized controlled trials are expected to clarify optimal indications, protocols, and long-term safety profiles. Clinicians are encouraged to consider enrollment of eligible patients in clinical studies and to monitor for evolving guideline recommendations as evidence matures.

Conclusion

Regenerative mucosal therapies represent a transformative frontier in the management of refractory ENT disorders, addressing fundamental defects in mucosal repair and function. While early evidence is promising, further high-quality research is required to define their role, refine delivery methods, and ensure long-term safety and efficacy. Integration of regenerative strategies into clinical practice has the potential to improve outcomes for patients with chronic, treatment-resistant ENT diseases, heralding a new era of personalized, mechanism-based therapy.